Lecigon (carbidopa/levodopa/entacapone) / LobSor - LARVOL DELTA

Understanding the Impact of the Small Scale Levodopa-Entacapone-Carbidopa-Intestinal-Gel Pump on Everyday Experiences of People Living with Parkinson’s Disease: A Mixed-Methods Evaluation (MDS Congress 2026) - No abstract available

CNS Disorders • Movement Disorders • Parkinson's Disease

Effectiveness of Switching from Levodopa-Carbidopa Intestinal Gel to Levodopa-Carbidopa-Entacapone Intestinal Gel in Patients with Refractory Biphasic and Peak-of-Dose Dyskinesia (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders • Movement Disorders

Levodopa–Entacapone–Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: a Four-Year Real-Life Experience (MDS Congress 2026) - No abstract available

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Provides Sustained Improvement In Quality Of Life In Advanced Parkinson’s For Up To Two Years (MDS Congress 2026) - No abstract available

HEOR • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Demographic And Clinical Characteristics Of Advanced Parkinson’s Disease Patients Receiving Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In The ELEGANCE Study: An Updated Interim Analysis (MDS Congress 2026) - No abstract available

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Wearable assessment of levodopa-entacapone- carbidopa intestinal gel treatment characteristics at home: Pilot Protocol (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders

2501 : Troubleshooting Parkinson's Disease: Infusion Therapies in the Clinic (MDS Congress 2026) - "In this session, the faculty will use case-based discussions to demonstrate key considerations for patient selection for infusion therapies, factors influencing selection of Levodopa-carbidopa intestinal gel (LCIG) / Levodopa-entacapone-carbidopa intestinal gel (LECIG) or subcutaneous preparations and setting patient and clinician expectations. Participants will learn to recognize the clinical scenarios where escalation to infusion therapies may be appropriate. Learning Objectives At the conclusion of this session, participants should be better able to: Recognize indications for initiation and selection of infusion therapies in people with Parkinson’s disease Apply infusion therapies for the management of motor and non-motor fluctuations in Parkinson’s disease Screen for, assess, and manage emergent complications of infusion therapies"

CNS Disorders • Movement Disorders • Parkinson's Disease

Comparative outcomes and healthcare costs of three device-aided pharmacotherapies for patients with advanced Parkinson's disease in Sweden: A nationwide registry-based cohort study. (PubMed, Parkinsonism Relat Disord) - "In this nationwide Swedish cohort, no statistically significant mortality difference was detected. Weighted one-year HCRU and cost estimates were lower among LC-5 users than among infusion-therapy users; however, residual confounding by disease severity, treatment selection, and other unmeasured clinical factors limits causal interpretation."

HEOR • Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Baseline dopaminergic treatment profiles of patients with advanced Parkinson’s disease prior to Levodopa-Entacapone-Carbidopa intestinal gel infusion (EAN 2026) - "Most patients also had treatment with dopamine agonists (82%; pramipexole n = 10, 2.35 ± 0.87 mg; ropinirole n = 11, 12.36 ± 5.5 mg; rotigotine patch n = 21, 8.48 ± 1.89 mg) as well as selective monoamine oxidase B inhibitors (MAO-Bi, 60%, n = 30), apomorphine pen (14%, n = 7), Amantadine (28%, n = 14) and Entacapone (70%, n = 35). The usage of dopaminergic treatments in patients with APD prior to LECIG treatment was more complex than those described in the literature. Such analyses help general neurologists identify the limits of conventional dopaminergic therapy and prompt timely referral to tertiary centers."

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Outcome of People with Parkinson´s Disease Treated with Levodopa-entacapone-carbidopa Intestinal Gel Who Failed Previous Foslevodopa/Foscarbidopa (EAN 2026) - "LECIG could be a good therapeutic option in PwP who failed fLD/fCD."

Alzheimer's Disease • CNS Disorders • Dementia • Movement Disorders • Parkinson's Disease

HOC09 EAN/MDS-ES: Infusion therapies management in advanced Parkinson’s disease (Level 2) (EAN 2026) - "Considered infusion therapies will include: continuous subcutaneous apomorphine infusion (CSAI), Levodopa/carbidopa intestinal gel infusion (LCIG), Levodopa/entacapone/carbidopa intestinal gel (LECIG) and Levodopa/carbidopa continuous subcutaneous infusion (LC‑CSCI). Clinical indications, dose titration and adjustment and adverse events management will be discussed.This session is supported with the equipment provided by:AbbVie,Nordic Infucare,STADA Specialty Care."

Metastases • CNS Disorders • Movement Disorders • Myelodysplastic Syndrome • Parkinson's Disease

Individualisation of LECIG therapy in advanced Parkinson’s disease: adapting treatment to suit patients’ lives (EAN 2026) - "Levodopa–entacapone–carbidopa intestinal gel (LECIG) is a device-aided therapy for advanced PD designed to allow flexible dosing, enabling adaptation to patients’ specific and fluctuating motor needs throughout the day. The use of multiple flow rates with the Crono® LECIG pump allows individualised medication delivery aligned with daily activities and symptom fluctuations, supporting functional independence and an active lifestyle. MS and related disorders 5"

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

SWITCH-ON: Prospective, observational study of LECIG efficacy in Parkinson’s disease patients previously treated with subcutaneous foslevodopa (EAN 2026) - P | "Background and aims: Levodopa–entacapone–carbidopa intestinal gel (LECIG) is a device-aided therapy (DAT) for advanced Parkinson's disease (PD) patients who have severe motor fluctuations and hyperkinesia/dyskinesia that persists despite treatment with optimised oral therapy combinations (Figure 1). Subcutaneous (SC) infusion of foslevodopa/foscarbidopa (Fos) is an alternative DAT option in this setting... SWITCH-ON hopes to demonstrate that intrajejunal therapy can be a feasible option after Fos, and that prior SC treatment failure is not the end of the road for patients."

Clinical • Observational data • CNS Disorders • Movement Disorders • Parkinson's Disease

Patient perceptions of the Crono® LECIG pump device in advanced Parkinson’s disease treatment – data from the ELEGANCE observational study (EAN 2026) - P | "Background and aims: Levodopa–entacapone–carbidopa intestinal gel (LECIG) infusion is a treatment option for advanced Parkinson's disease (PD). Higher device satisfaction scores in those who switched from another pump therapy, suggest the Crono® LECIG pump may address some limitations of other devices. These findings highlight the critical role of patient-reported outcomes in evaluating drug-delivery developments in PD."

Clinical • Metastases • Observational data • CNS Disorders • Movement Disorders • Parkinson's Disease

Assessing the impact of levodopa–entacapone–carbidopa intestinal gel infusion in clinical practice: patient‑centred real‑world insights (EAN 2026) - No abstract available

Clinical • Real-world • Real-world evidence • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease

Longterm efficacy and safety of levodopa/entacapone/carbidopa intestinal gel in patients with advanced Parkinson’s disease in Slovakia (EAN 2026) - No abstract available

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

SWITCH-ON: Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease (clinicaltrials.gov) - P=N/A | N=215 | Recruiting | Sponsor: Britannia Pharmaceuticals Ltd. | Initiation date: Jan 2026 ➔ May 2026

Trial initiation date • CNS Disorders • Movement Disorders • Parkinson's Disease

Designing device-aided therapies for advanced Parkinson’s patients that aim to enhance patient care – the development of LECIGON® intestinal gel infusion (WPC 2026) - "Levodopa–entacapone–carbidopa intestinal gel (LECIGON®, d0dLECIG) was introduced in 2018 in Europe as a DAT option and was designed specifically to address feedback from PwAP and clinicians to improve convenience and usability. It enables PwAP to maintain an active and independent lifestyle, especially benefiting those who are frail, have limited strength, or low body weight. The pump is designed to be quiet and discreet, so is easy to wear in social situations and for daily activities."

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Device-aided therapy in advanced Parkinson’s should support an active daily life – A case study from Spain of treatment with LECIGON® intestinal gel infusion (WPC 2026) - "Levodopa–entacapone–carbidopa intestinal gel (LECIGON®, LECIG) was introduced in 2018 in Europe as a DAT option for PwAP and has been specifically designed with features that aim to improve their overall treatment experience. She reports having experienced fewer dyskinesias, greater motor stability, and an overall improvement in her quality of life. Being a highly active person – she plays competitive table tennis and padel and also skis — she particularly values the smaller size and portability of the Crono LECIG pump, which has significantly enhanced her comfort and confidence."

Case study • Clinical • Metastases • CNS Disorders • Dystonia • Movement Disorders • Parkinson's Disease

Significant correlation between patient and clinician perceptions of disease improvement with levodopa–entacapone–carbidopa intestinal gel (LECIG) in advanced Parkinson’s – data from the ELEGANCE interim analysis (WPC 2026) - P | "Reports from both clinicians and PD patients showed a significant correlation a with sustained favourable improvements in the patients’ disease following treatment with LECIG for up to one year compared with their baseline condition. Reference 1. Senek M, et al."

Clinical • Metastases • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease

Understanding patient perceptions of treatment with levodopa–entacapone–carbidopa intestinal infusion – real world insights from the ELEGANCE study (WPC 2026) - P | "Patient satisfaction with PD therapy is an important factor that may contribute to treatment continuation. This analysis demonstrated patients were satisfied with the small, quiet and lightweight LECIG pump, and high satisfaction scores were sustained for up to two years. Reference 1."

Clinical • Real-world • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

The Klem ring: A patient-approved enhancement to the LECIGON® (levodopa–entacapone–carbidopa intestinal gel) delivery system for the treatment of advanced Parkinson’s (WPC 2026) - "By listening to clinician and patient feedback and making small design changes to components of the PEG-J system the overall treatment experience for LECIG-treated PD patients has improved. The inconvenience and additional time in hospital due to jejunal tube dislocations has reduced. References: (1) Weiss D, et al."

Clinical • Metastases • CNS Disorders • Movement Disorders • Parkinson's Disease

Nationwide analysis of real-world access to and use of device-aided therapies in Parkinson's disease: insights from the French National Healthcare Data System (2015-2021). (PubMed, BMJ Neurol Open) - "They now include deep brain stimulation (DBS), levodopa-carbidopa intestinal gel (LCIG) infusion, continuous subcutaneous apomorphine infusion (CSAI), subcutaneous foslevodopa/foscarbidopa and levodopa-entacapone-carbidopa intestinal gel (LECIG) infusions. Unlike patterns observed in other countries, CSAI was the predominant DAT in France, while DBS use declined. Features of the French healthcare system, including favourable reimbursement and broad access to home nursing services, may account for this distinctive distribution."

Journal • Real-world evidence • CNS Disorders • Movement Disorders • Parkinson's Disease

Levodopa-entacapone-carbidopa intestinal gel in advanced Parkinson's disease: an analysis of interim data for Romanian patients enrolled in the ELEGANCE study. (PubMed, J Neural Transm (Vienna)) - P | "LECIG treatment for up to one year of APD patients at Romanian centers provided effective control of motor symptoms and was well tolerated, with few discontinuations. Additional benefit was observed on some NMS, in particular sleep, and in QoL."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • Sleep Disorder

Recent Developments in the Drug Treatment of Parkinson's Disease. (PubMed, Drugs) - "Novel formulations and modes of application include extended-release (ER) oral levodopa (IPX203), levodopa powder for inhalation, and levodopa infusion therapies through subcutaneous (foslevodopa/foscarbidopa, ND0612) or intrajejunal pumps (levodopa [entacapone] carbidopa intestinal gel)...Novel dopamine agonists have been developed and tavapadon, a selective dopamine D1/D5 receptor partial agonist, was shown to be efficacious as monotherapy in early PD and adjunct to levodopa in patients with motor fluctuations. In addition, new data on the early use of the COMT-inhibitor opicapone have emerged. This expanding drug armamentarium is complemented by an increasing number of drugs targeting non-dopaminergic pathways with increasing evidence for amantadine's symptomatic efficacy in treating levodopa-induced dyskinesia and motor fluctuations...PD symptoms can usually be satisfactorily controlled in the early to mid-stages, but the progressive course of the disease..."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT • LRRK2